Trial reportPsychopharmacology2014
Opposing neural effects of naltrexone on food reward and aversion: implications for the treatment of obesity.
Trial report in Psychopharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 3 syntheses or guidelines pooled it, 57 citations in OpenAlex.
- Neural Correlates of Anti-appetite Medications: An fMRI Meta-analysis.Current neuropharmacology · 2021Pooled it
- Hunger and BMI modulate neural responses to sweet stimuli: fMRI meta-analysis.International journal of obesity (2005) · 2020Pooled it
- Can neuroimaging help combat the opioid epidemic? A systematic review of clinical and pharmacological challenge fMRI studies with recommendations for future research.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2019Pooled it
- Effects of dopamine and opioid receptor antagonism on the neural processing of social and nonsocial rewards.Human brain mapping · 2024Trial
- Effects of Mu-Opiate Receptor Gene Polymorphism rs1799971 (A118G) on the Antidepressant and Dissociation Responses in Esketamine Nasal Spray Clinical Trials.The international journal of neuropsychopharmacology · 2020Trial
- Effects of extended-release naltrexone on the brain response to drug-related stimuli in patients with opioid use disorder.Journal of psychiatry & neuroscience : JPN · 2018Trial
- Dopamine D2/3- and μ-opioid receptor antagonists reduce cue-induced responding and reward impulsivity in humans.Translational psychiatry · 2016Trial
- Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers.The international journal of neuropsychopharmacology · 2014Trial
- The Neural and Perceptual Effects of Stevia During Retronasal Occlusion.The European journal of neuroscience · 2026Article
- The role of the caudate nucleus in taste function: a comprehensive narrative review.Frontiers in neuroscience · 2026Review
- Retro nasal blockade reduces the neural processing of sucrose in the human brain.IBRO neuroscience reports · 2025Article
- Integrative Hedonic and Homeostatic Food Intake Regulation by the Central Nervous System: Insights from Neuroimaging.Brain sciences · 2022Review
- Brain Responses to High-Calorie Visual Food Cues in Individuals with Normal-Weight or Obesity: An Activation Likelihood Estimation Meta-Analysis.Brain sciences · 2021Review
- Tobacco withdrawal increases junk food intake: The role of the endogenous opioid system.Drug and alcohol dependence · 2021Article
- Pharmacological fMRI provides evidence for opioidergic modulation of discrimination of facial pain expressions.Psychophysiology · 2021Article
- The role of the opioid system in decision making and cognitive control: A review.Cognitive, affective & behavioral neuroscience · 2019Review
- Neural vulnerability factors for obesity.Clinical psychology review · 2019Review
- Neuropharmacology of compulsive eating.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2018Review
- Hyperpalatability and the Generation of Obesity: Roles of Environment, Stress Exposure and Individual Difference.Current obesity reports · 2018Review
- The effectiveness of naltrexone combined with current smoking cessation medication to attenuate post smoking cessation weight gain: a literature review.Journal of pharmaceutical policy and practice · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
rationaleOpioid antagonism reduces the consumption of palatable foods in humans but the neural substrates implicated in these effects are less well understood.
objectivesThe aim of the present study was to examine the effects of the opioid antagonist, naltrexone, on neural response to rewarding and aversive sight and taste stimuli.
methodsWe used functional magnetic resonance imaging (fMRI) to examine the neural responses to the sight and taste of pleasant (chocolate) and aversive (mouldy strawberry) stimuli in 20 healthy volunteers who received a single oral dose of naltrexone (50 mg) and placebo in a double-blind, repeated-measures cross-over, design.
resultsRelative to placebo, naltrexone decreased reward activation to chocolate in the dorsal anterior cingulate cortex and caudate, and increased aversive-related activation to unpleasant strawberry in the amygdala and anterior insula.
conclusionsThese findings suggest that modulation of key brain areas involved in reward processing, cognitive control and habit formation such as the dorsal anterior cingulate cortex (dACC) and caudate might underlie reduction in food intake with opioid antagonism. Furthermore we show for the first time that naltrexone can increase activations related to aversive food stimuli. These results support further investigation of opioid treatments in obesity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.